Spirulina and sarcoidosis: granuloma NOX2, vitamin D hypercalcaemia risk, corticosteroids, and fatigue

Sarcoidosis pathophysiology

Granuloma formation: An unidentified antigen (proposed: mycobacterial components, propionibacterial antigens, or inorganic particles) activates alveolar macrophages via TLR signalling. Macrophages present antigen to CD4+ T cells, which differentiate into Th1 (IFN-γ producing) cells. Th1 IFN-γ further activates macrophages, which fuse into epithelioid cells and multinucleated giant cells forming the granuloma. TNF-α and IL-12 are the central cytokines. NF-κB activation in macrophages drives the self-amplifying granulomatous inflammatory cycle.
NOX2 in granuloma macrophages: Activated macrophages and epithelioid cells within granulomas express NOX2 abundantly. NOX2-derived superoxide contributes to granuloma maintenance and to tissue damage at granuloma sites (lung fibrosis, cardiac sarcoidosis, hepatic granulomas). Phycocyanobilin’s NOX2 inhibition is mechanistically aligned with reducing this granulomatous oxidative inflammation.
NK stimulation concern: Sarcoidosis is primarily Th1 macrophage-driven. NK cells are not primary effectors in sarcoidosis granuloma formation or maintenance. The NK stimulation concern is low in sarcoidosis not treated with immunosuppressants. On prednisolone or other immunosuppressants: apply the standard immunosuppressive NK concern framework.

CYP27B1 in granuloma macrophages: Sarcoidosis granuloma macrophages express CYP27B1 (1-alpha hydroxylase), the enzyme that converts 25-hydroxyvitamin D (calcidiol) to the active 1,25-dihydroxyvitamin D₃(calcitriol). This conversion is normally tightly regulated in the kidney but is unregulated in granuloma macrophages, producing excess active vitamin D regardless of serum level. The result: hypercalciuria, hypercalcaemia, nephrocalcinosis, and renal impairment in sarcoidosis patients exposed to high vitamin D intake or UV light.
Spirulina vitamin D content: Spirulina contains trace vitamin D (<1 µg/10 g — effectively negligible). This is not a meaningful source of vitamin D and does not contribute to hypercalcaemia risk. The concern is specifically about co-supplementing vitamin D₃supplements alongside spirulina in sarcoidosis — do not add vitamin D supplements without specialist guidance.
Beta-carotene (provitamin A) is safe: Spirulina’s beta-carotene (~1,500–2,000 µg/5 g) is converted to retinol (vitamin A) as needed via intestinal cleavage. This is a different vitamin to vitamin D and is not involved in the CYP27B1 pathway. Beta-carotene from spirulina is safe in sarcoidosis.

Fatigue is the most common and debilitating symptom in sarcoidosis, affecting 50–70% of patients and persisting even in radiological remission. Mechanisms include: small-fibre neuropathy, central neuroinflammation from granulomatous neurosarcoidosis, iron deficiency (common in chronic inflammatory disease via hepcidin induction), sleep disruption, and HPA axis dysfunction from granulomatous adrenal involvement.
Spirulina addresses iron deficiency (use transferrin saturation not ferritin for assessment in active sarcoidosis), provides complete protein for mitochondrial function, and phycocyanobilin may reduce central neuroinflammatory contribution to fatigue via NF-κB inhibition.

First-line for pulmonary, cardiac, neurological, and ocular sarcoidosis. No pharmacokinetic interaction with spirulina. NK concern at immunosuppressive doses (≥15–40 mg/day); discuss with prescribing physician. At maintenance doses (≤10 mg/day): lower concern.

HCQ is used in sarcoidosis for skin lesions (lupus pernio), fatigue, and hypercalcaemia (HCQ reduces CYP27B1 activity in macrophages, lowering 1,25(OH)₂D₃production). No pharmacokinetic interaction with spirulina. HCQ and spirulina both have NF-κB-inhibiting effects via different mechanisms (complementary). No NK stimulation concern with HCQ alone.

Low-dose methotrexate used as steroid-sparing agent in chronic sarcoidosis. No pharmacokinetic interaction with spirulina. Intermediate NK concern; discuss with specialist.

Used in refractory or steroid-dependent sarcoidosis. No pharmacokinetic interaction. Intermediate NK concern; discuss with prescribing physician.

Sarcoidosis on no immunosuppressants (watchful waiting or HCQ only): NK concern is low; 3–5 g/day spirulina appropriate; inform specialist
Sarcoidosis on prednisolone ≥15 mg/day: intermediate NK concern; discuss with respiratory physician
CRITICAL: do not add vitamin D supplements in sarcoidosis without specialist approval (CYP27B1 hypercalcaemia risk); spirulina vitamin D content is negligible and safe
Fatigue: check transferrin saturation (not ferritin) for iron status; check calcium and vitamin D before supplementing any D-containing products
Sun exposure: avoid excessive UV in hypercalciuric sarcoidosis (UV synthesises cutaneous vitamin D₃); spirulina photoprotective effects via beta-carotene are relevant here